275386-53-3

Upstream product

• 120042-01-5 2-Bromo-5,6-dimethyl-1,4-hydroquinone 
• 608-43-5 2,3-dimethyl-1,4-dihydroxybenzene 

Downstream Products

• 38969-08-3 2,3-dibromo-5,6-dimethylcyclohexa-2,5-diene-1,4-dione 

Relevant academic research and scientific papers

Novel plastoquinone analogs containing benzocaine and its analogs: structure‐based design, synthesis, and structural characterization

Introducing new biologically active organic molecules or their analogs into the pharmaceutically important molecules significantly enables the discovery and development of the medicines that improve the health of patients. Chemical synthesis has a key role in pharmaceutical research and development, aiming to design and build molecules with the essential biological activity needed in drugs. For that reason, herein, three series of novel PQ analogs (the nonhalogenated (PQ1-6) and the halogenated PQ analogs (BrPQ1-6 and ClPQ1-6)) containing benzocaine and its analogs were designed and synthesized starting from the commercially available dimethylhydroquinone (1) with benzocaine and its analogs. The structures of all synthesized analogs were characterized by using spectroscopic methods. The in vitro antibacterial and antifungal activities were evaluated for the PQ analogs.

Brominated plastoquinone analogs: Synthesis, structural characterization, and biological evaluation

A series of brominated PQ analogs (BrPQ1-13) was synthesized by employing two different routes: 1) dibromination followed by oxidation and amination of dimethyl hydroquinone, respectively, 2) oxidation of dimethyl hydroquinone followed by amination and bromination, respectively. In addition to the single-crystal X-ray structural characterization of two analogs (BrPQ2 and BrPQ3), the structures of all analogs were determined based on spectral (FTIR, 1H NMR, 13C NMR, and HRMS) data. We evaluated the analogs for in vitro antibacterial and antifungal activity against ATCC strains (panel of seven bacterial strains with three Gram-positive and four Gram-negative bacteria and three fungi) using the broth microdilution method. The structure–activity relationship of brominated PQ analogs indicated that the electron-withdrawing group (EWG) on the phenyl ring (-CF3, trifluoromethyl group) has a positive effect on antibacterial activity. These in vitro data show that brominated analogs, especially for BrPQ 1, BrPQ2, and BrPQ3, have the potential to be developed as new antibacterial agents against S. aureus and/or S. epidermidis with low MIC values.

2-Amino-1,2,3-triazole derivatives

The syntheses and structure of 2-triarylphosphoranimine-1,2,3-triazole derivatives from vicinal diazides have been investigated. Compounds derived from dichloronapththoquinone, 2,3-dichloro-5,6-dimethylbenzoquinone, and 2,3,5,6-tetrachlorobenzoquinone are included. X-ray structures, NMR, IR, UV, and cyclic voltammetry data are reported. Compound 2 crystallizes in space group P1 with a = 12.31(1), b = 12.469(3), c = 10.088(3) A, a = 97.19(3), β = 103.79(6), γ = 101.84(4)o, and Dcalc = 1.466 g/cm for Z = 2. Compound 4 crystallizes in space group P21l c with a = 9.044(2), b = 10.882(2), c = 19.110(4) A, β = 99.06(2)o, and Dcalc = 1.324 g/cm for Z = 2. Compound 6 crystallizes in space group P21/a with a = 8.85(1), b = 14.841(8), c = 11.372(8) A, β = 107.19(3)o, and Dcalc = 1.397 g/cm for Z = 4. Compound 11 crystallizes in space group P21/n with a = 8.823(3), b = 16.501(6), c = 16.221(3) A, β = 103.58(2)o, and Dcalc = 1.309 g/cm for Z = 4. Compound 12 crystallizes in space group P1 with a = 11.606(8), b = 11.671(5), c = 10.734(3) A, α = 101.62(3), β = 93.70(4), γ = 64.33(4)o, and Dcalc = 1.438 g/cm for Z = 2. Compound 13 crystallizes in space group C2/c with a = 13.337(7), b = 9.217(6), c = 24.78(1) A, β = 102.85(5)o, and Dcale = 1.478 g/cm for Z = 8.